Arbutus’ LNP Licensee Alnylam Announces Positive Phase 3 Results for LNP-Enabled Patisiran Program
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/8/2026
- S&P 500 falls as AI worries hit software makers
- Brent crude hits six-week high near $97 as Houthi strike targets Saudi Aramco
- Qualcomm stock surges 9.5% on Amazon AI deal & 25M share warrant
- Energy stocks rise premarket as oil prices climb on Middle East supply fears
- Novartis shares plunge 10% as failed drug trial clouds growth outlook
- Harry and Meghan surprised by King Charles' letter on their status
- Citi initiates UiPath coverage with Buy rating and $23 target
- S&P 500 falls as AI worries hit software makers
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- After an 18% summer selloff in chip stocks, Citi asks what comes next
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Alnylam Pharmaceuticals (ALNY) PT Raised to $123 at Credit Suisse
September 21, 2017 6:26 AM EDTCredit Suisse analyst Alethia Young raised her price target on Alnylam Pharmaceuticals (NASDAQ: ALNY) to $123.00 (from $96.00) while maintaining an Outperform rating following positive APOLLO trial data.
Young thinks porphyria data in mid-2018 and patisiran's expansion into the cardiac subtype can continue... More
Alnylam Pharmaceuticals (ALNY) PT Raised to $125 at Needham & Company
September 20, 2017 3:20 PM EDTNeedham & Company analyst Alan Carr raised his price target on Alnylam Pharmaceuticals (NASDAQ: ALNY) to $125.00 (from $85.00) while maintaining a Buy rating after the company announced positive top-line results from Phase 3 APOLLO trial in TTR Amyloidosis.
"Notably, primary mNIS+7 and key secondary Norfolk QOL-DN endpoint... More
Alnylam Pharmaceuticals (ALNY) PT Raised to $128 at JMP Securities
September 20, 2017 2:14 PM EDTJMP Securities analyst Michael King raised his price target on Alnylam Pharmaceuticals (NASDAQ: ALNY) to $128.00 (from $101.00) while maintaining a Market Outperform rating after the company announced positive top-line results for the Phase III APOLLO trial.
"We believe patisirans success in APOLLO... More
Alnylam Pharmaceuticals (ALNY) PT Raised to $83 at Stifel
September 20, 2017 1:41 PM EDTStifel raised its price target on Alnylam Pharmaceuticals (NASDAQ: ALNY) to $83.00 (from $56.00) while maintaining a Hold rating.
... MoreAlnylam Pharmaceuticals (ALNY) PT Raised to $117 at Cowen; 'Best-Case Scenario'
September 20, 2017 12:36 PM EDTCowen raised its price target on Alnylam Pharmaceuticals (NASDAQ: ALNY) to $117.00 (from $93.00) while maintaining a Outperform rating after the company released positive top-line data from the pivotal Ph3 APOLLO trial of patisiran in FAP with strong statistical significance.
Analyst Ritu Baral... More
